Texas Institute for Neurological Disorders
Welcome,         Profile    Billing    Logout  
 19 Trials 
34 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lynch, Sharon G
REMODEL-2, NCT05156281 / 2020-005929-89: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, Canada, Japan, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
ALITHIOS, NCT03650114 / 2017-004703-51: Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Calendar Jan 2028 - Dec 2028: Data from ALITHIOS trial for multiple sclerosis
Recruiting
3
2060
Europe, Canada, Japan, US, RoW
Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
12/27
09/28
NCT05798520: A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

Recruiting
2
275
Europe, US, RoW
BIIB091, DRF, Placebo
Biogen
Relapsing Forms of Multiple Sclerosis
07/25
11/26
MoveS-it, NCT04602390: Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis

Completed
1
33
US
ANK-700, Placebo
Anokion SA
Multiple Sclerosis (MS), Relapsing Remitting Multiple Sclerosis
04/24
04/24
NCT02740361: Online Program to Reduce Depression in MS

Active, not recruiting
N/A
400
Europe, US
Deprexis, DeprexisPlus
Charite University, Berlin, Germany, National Multiple Sclerosis Society, Universitätsklinikum Hamburg-Eppendorf, Cedars-Sinai Medical Center, University of Missouri, Kansas City, Penn State University, King's College London, University Medical Center Goettingen, NeuroCure Clinical Research Center, Charite, Berlin
Multiple Sclerosis
01/21
12/21
TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Recruiting
N/A
900
US
Natalizumab, Alemtuzumab, Ocrelizumab, Rituximab, Cladribine, Ofatumumab, Ublituximab-xiiy, Tysabri, Lemtrada, Ocrevus, Rituxan, Mavenclad, Kesimpta, Briumvi, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso
Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Multiple Sclerosis, Relapsing-Remitting
08/25
08/25
Levine, Todd D
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
235
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
05/25
03/28
ENSURE-2, NCT05201638 / 2021-000029-28: Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Recruiting
3
1050
Europe, US, RoW
IMU-838 tablets, Vidofludimus calcium, Placebo matching IMU-838 tablets, Placebo matching vidofludimus calcium
Immunic AG, Immunic AG
Multiple Sclerosis, Relapsing-Remitting
10/24
10/32
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
ATLAS, NCT04856982 / 2020-004590-51: A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

Recruiting
3
150
Europe, Canada, Japan, US, RoW
Tofersen, BIIB067, QALSODY, Placebo
Biogen
Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
08/27
08/27
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, Japan, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
NCT05650567: Study of M5049 in DM and PM Participants (NEPTUNIA)

Recruiting
2
40
Europe, US, RoW
M5049 high dose, Enpatoran, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Dermatomyositis, Polymyositis
04/25
04/25
ARDA+, NCT05405361 / 2021-004998-32: A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults with Multifocal Motor Neuropathy

Active, not recruiting
2
51
Europe, Canada, US
ARGX-117, Placebo
argenx, argenx BV
Multifocal Motor Neuropathy (MMN)
09/26
09/26
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29
NCT04700722: Synuclein-One Study

Completed
N/A
428
US
Skin Biopsy
CND Life Sciences
Parkinson Disease, Multiple System Atrophy, Dementia With Lewy Bodies, Pure Autonomic Failure
12/22
11/23
NCT05479552: A Diagnostic Test for Dementia With Lewy Bodies

Active, not recruiting
N/A
80
US
Syn-One Test
CND Life Sciences, National Institute on Aging (NIA)
MCI-AD, Early Stage Alzheimer's Disease, MCI-DLB, Early Stage Dementia With Lewy Bodies
09/25
10/25
FF-1, NCT06621602: Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease

Recruiting
N/A
100
US
CND Life Sciences, Michael J. Fox Foundation for Parkinson's Research
REM Behavior Disorder, Parkinson Disease
04/26
04/26
NCT05757206: The Syn-Sleep Study

Active, not recruiting
N/A
80
US
Syn-One Test
CND Life Sciences
REM Sleep Behavior Disorder (iRBD)
12/25
12/25
Groezinger, Katy
ALITHIOS, NCT03650114 / 2017-004703-51: Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Calendar Jan 2028 - Dec 2028: Data from ALITHIOS trial for multiple sclerosis
Recruiting
3
2060
Europe, Canada, Japan, US, RoW
Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
12/27
09/28
RESOLUTION, NCT04417257: Study of LAU-7b for the Treatment of COVID-19 Disease in Adults

Completed
2/3
125
Canada, US
LAU-7b, fenretinide, Placebo oral capsule
Laurent Pharmaceuticals Inc.
COVID-19 Disease
02/24
05/24
ENDOLOW, NCT04167527: Endovascular Therapy for Low NIHSS Ischemic Strokes

Recruiting
2/3
200
Europe, Canada, US
Immediate mechanical thrombectomy(iMT) using EmboTrap Revascularization Device, EmboTrap III, Initial medical management (iMM)
Emory University, University of Calgary, University of Cincinnati, Heidelberg University, Children's Hospital Medical Center, Cincinnati
Cerebral Ischemia
12/24
12/24
NCT02844465: Stereotactic Laser Ablation for Temporal Lobe Epilepsy (Slate)

Completed
N/A
167
US
Visualase MRI-Guided Laser Ablation, Visualase System, Visualase procedure, Laser interstitial thermal therapy, Stereotactic laser ablation
MedtronicNeuro
Temporal Lobe Epilepsy
12/23
12/23
Hall, Sarah
ALITHIOS, NCT03650114 / 2017-004703-51: Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Calendar Jan 2028 - Dec 2028: Data from ALITHIOS trial for multiple sclerosis
Recruiting
3
2060
Europe, Canada, Japan, US, RoW
Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
12/27
09/28
NCT06176898: Neurostimulation in Intermittent Claudication

Recruiting
N/A
16
Europe
Neurostimulating device
The Leeds Teaching Hospitals NHS Trust
Claudication
12/23
12/23
Ismail, Farah
PDGENE, NCT04057794: PDGeneration: Mapping the Future of Parkinson's Disease

Active, not recruiting
N/A
1982
US
Lab Assay for seven genetic variants for Parkinson's Disease
Parkinson's Foundation, Fulgent Laboratories, Indiana University, The Parkinson Study Group, Navitas Clinical Research, Inc
Parkinson's Disease and Parkinsonism
12/21
04/25
FF-1, NCT06621602: Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease

Recruiting
N/A
100
US
CND Life Sciences, Michael J. Fox Foundation for Parkinson's Research
REM Behavior Disorder, Parkinson Disease
04/26
04/26
NCT05757206: The Syn-Sleep Study

Active, not recruiting
N/A
80
US
Syn-One Test
CND Life Sciences
REM Sleep Behavior Disorder (iRBD)
12/25
12/25
Schrader, Julie
C4951003, NCT04743141: Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

Recruiting
3
200
Europe, US
Rimegepant (PF-07899801)
Pfizer
Acute Treatment of Migraine
06/27
06/27
REMODEL-2, NCT05156281 / 2020-005929-89: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, Canada, Japan, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
NCT04649242 / 2020-003517-35: Randomized Study in Children and Adolescents With Migraine: Acute Treatment

Recruiting
3
2100
Europe, Canada, Japan, US, RoW
Rimegepant/BHV3000, Matching placebo
Pfizer
Pediatric Migraine
01/29
01/29
Mayakrishnan, Indu
NCT05757206: The Syn-Sleep Study

Active, not recruiting
N/A
80
US
Syn-One Test
CND Life Sciences
REM Sleep Behavior Disorder (iRBD)
12/25
12/25
Jarvis, Laurie
NCT05757206: The Syn-Sleep Study

Active, not recruiting
N/A
80
US
Syn-One Test
CND Life Sciences
REM Sleep Behavior Disorder (iRBD)
12/25
12/25
Ham, Michelle
REMODEL-2, NCT05156281 / 2020-005929-89: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, Canada, Japan, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
Conte, William
REMODEL-2, NCT05156281 / 2020-005929-89: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, Canada, Japan, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30

Download Options